Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC -0.89%55 EV-to-EBIT is 9.52 as of Jul. 22, 2026, which is 29% below its 10-year median of 13.42. GuruFocus rates FRA:PDC with a GF Score™ of 55/100 and a GF Value™ of €11.20. The stock has 8 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 76.71% on this metric.
The historical rank and industry rank for Pediatrix Medical Group's EV-to-EBIT or its related term are showing as below:
FRA:PDC'
s EV-to-EBIT Range Over the Past 10 Years
Min: -214.93 Med: 13.42 Max: 35.66
Current: 9.33
During the past 13 years, the highest EV-to-EBIT of Pediatrix Medical Group was 35.66. The lowest was -214.93. And the median was 13.42.
FRA:PDC's EV-to-EBIT is ranked better than 76.71% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 15.775
vs FRA:PDC: 9.33
Pediatrix Medical Group (FRA:PDC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pediatrix Medical Group's Enterprise Value for the quarter that ended in Mar. 2026 was €1,737 Mil.
Pediatrix Medical Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €225 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pediatrix Medical Group EV-to-EBIT Related Terms
Pediatrix Medical Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Pediatrix Medical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's EV-to-EBIT falls into.
Pediatrix Medical Group's current Enterprise Value is €2,144 Mil.
Pediatrix Medical Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €225 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pediatrix Medical Group (FRA:PDC) has a EV-to-EBIT of 9.52 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pediatrix Medical Group and its competitors. This is 29% below median its historical median of 13.42. According to the industry distribution chart, Pediatrix Medical Group ranks #109 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 23.3%.
Is Pediatrix Medical Group's EV-to-EBIT too high?
Pediatrix Medical Group's current EV-to-EBIT of 9.52 is 29% below median its 10-year median of 13.42. The Healthcare Providers & Services industry median EV-to-EBIT is 15.78. Pediatrix Medical Group's value of 9.52 is 39.7% below this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #109 out of 468 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pediatrix Medical Group has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's EV-to-EBIT compare to SEM and AGL?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #109 out of 468 companies for EV-to-EBIT. This places Pediatrix Medical Group in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.78. Pediatrix Medical Group's value of 9.52 is 39.7% below this benchmark. While the company's 10-year median is 13.42 vs. the industry median of 15.78, Pediatrix Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.78, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current EV-to-EBIT of 9.52 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pediatrix Medical Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current EV-to-EBIT is 9.52, which is 29% below median its own 10-year median of 13.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current EV-to-EBIT of 9.52. The stock's GF Value™ is €11.20, compared to a current price of €22.20 — trading 98.2% above its estimated fair value. The current EV-to-EBIT is 9.52, which is 29% below median its 10-year median of 13.42 and 39.7% below the Healthcare Providers & Services industry median of 15.78. Pediatrix Medical Group's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current EV-to-EBIT is 9.52 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €22.20 is trading 98.2% above its estimated GF Value™ of €11.20.
Key valuation signals for FRA:PDC:
EV-to-EBIT: 9.52 (29% below median its 10-year median of 13.42)
GF Value™: €11.20 vs. price of €22.20 (98.2% above fair value)
Industry Position: 39.7% below the Healthcare Providers & Services median (#109 of 468)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
55GF Score
Get the complete analysis for FRA:PDC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
